Cipla acquires 30 percent stake in Brandmed for Rs 32 crore

The acquisition of Brandmed is expected to complete by May 31. The transaction worth Rs 32 crore will be executed by the company's South African arm Cipla Medpro.

Mumbai: Pharmaceutical major Cipla Ltd is acquiring 30 per cent stake in South African company Brandmed to increase its exposure to the connected healthcare segment.

Besides the upfront cash payment, the transaction also involves milestone payments spread over three years on meeting profit targets. The transaction worth Rs 32 crore will be executed by the company's South African arm Cipla Medpro.

Read Also: Cipla, Pulmatrix join hands to co-develop Pulmazole for treating asthma

In February, Cipla had announced a similar partnership in India with Wellthy Therapeutics to offer a clinically-validated digital disease management platform to patients in cardio-metabolic health.

The company said in a statement that it expects to complete the transaction with Brandmed by May 31.

"This will help to transition healthcare from being reactive to a proactive and real-time monitoring model that focuses on promoting wellness instead of managing illness," said Paul Miller, Chief Executive Officer of Cipla Medpro.

Read Also: Cipla launches respiratory inhalation therapy product Niveoli in India

"By pairing our strengths with Brandmed' s innovative, patient-centric approach to healthcare, Cipla Medpro will enhance its diverse portfolio in the non-communicable disease area to provide holistic care to patients from awareness through to disease management, thereby enabling patient adherence and compliance."

Founded in 2014, Brandmed has developed an integrated solution to address outcomes and value-based care for patients with chronic lifestyle and non-communicable diseases.

Read Also: Cipla signs over Rs 152 crore pact with Pulmatrix for new asthma drug Pulmazole

According to the World Health Organisation, more than 38 million people die annually from non-communicable diseases like cardiovascular ailments, cancers, chronic respiratory disorders and diabetes.